Caligan Partners LP Has $29.72 Million Stake in Evolus, Inc. (NASDAQ:EOLS)

Caligan Partners LP lifted its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 22.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,692,388 shares of the company's stock after buying an additional 498,900 shares during the quarter. Evolus comprises 7.9% of Caligan Partners LP's holdings, making the stock its 4th biggest position. Caligan Partners LP owned 4.25% of Evolus worth $29,724,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of EOLS. KBC Group NV acquired a new stake in shares of Evolus in the fourth quarter valued at approximately $49,000. IFP Advisors Inc increased its position in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Evolus in the fourth quarter worth $106,000. Quantbot Technologies LP acquired a new position in Evolus in the fourth quarter valued at about $118,000. Finally, Freestone Grove Partners LP acquired a new stake in Evolus during the fourth quarter worth about $140,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on EOLS. BTIG Research initiated coverage on shares of Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus presently has a consensus rating of "Buy" and an average price target of $23.75.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. This trade represents a 1.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rui Avelar sold 27,904 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,575 shares of company stock worth $794,369 over the last three months. Company insiders own 6.10% of the company's stock.

Evolus Trading Down 2.2 %

NASDAQ EOLS traded down $0.26 on Tuesday, hitting $11.75. The company's stock had a trading volume of 434,454 shares, compared to its average volume of 665,017. The firm has a market cap of $757.53 million, a PE ratio of -12.92 and a beta of 1.11. The company's 50-day moving average is $11.94 and its 200 day moving average is $12.68. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.